MMP1 and prostate carcinoma: In-vitro activation of the RANKL/RANK pathway promoted increased metastatic potential and MMP-1 expression of the prostate cancer PC3 cell line, with an interesting decreased presence of osteoclastogenesis and osteolytic lesions following MMP-1 knockdown in a mouse model of metastasis [153].